Cannabis Therapeutics and the Future of Neurology Ethan B. RUSSO Frontiers in Integrative Neuroscience, 18 October 2018 https://doi.org/10.3389/fnint.2018.00051 Abstract : Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol [...]
Lire la suiteCannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders Hiroki Ishiguro, Yasue Horiuch, Koichi Tabata, Qing-Rong Liu, Tadao Arinami and Emmanuel S. Onaivi Molecules, 2018, 23, 1836; doi : 10.3390/molecules23081836 Abstract : CB2 cannabinoid receptor (CB2R) gene is associated with depression. We investigated the gene-environment interaction between CB2R function and diverse stressors. First, anxiety-like behavior during chronic-mild-stress (CMS) was evaluated in C57BL/6JJmsSlc mice following treatment with CB2R agonist JWH015 or inverse-agonist AM630. Second, locomotor activity and anxiety-like behavior were measured following exposure to an immune poly I:C stressor. Gene expressions of HPA axis related molecules, Fkbp5, Nr3c1 and Crf and [...]
Lire la suiteCannabinoid Delivery Systems for Pain and Inflammation Treatment Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi and Franco Dosio Molecules, 2018, 23, 2478 doi:10.3390/molecules23102478 www.mdpi.com/journal/molecules Abstract : There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and [...]
Lire la suiteChronic Adolescent D9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment Michelle Murphy,Sierra Mills, Joanna Winstone, Emma Leishman, Jim Wager-Miller, Heather Bradshaw, and Ken Mackie Cannabis and Cannabinoid Research, Volume 2.1, 2017 DOI: 10.1089/can.2017.0034 Abstract Introduction : The high prevalence of adolescent cannabis use, the association between this use and later psychiatric disease, and increased access to high-potency cannabis highlight the need for a better understanding of the long-term effects of adolescent cannabis use on cognitive and behavioral outcomes. Furthermore, increasing Δ9-tetrahydrocannabinol (THC) in high-potency cannabis is accompanied by a decrease in cannabidiol (CBD), thus [...]
Lire la suiteCannabis and Pain : A Clinical Review Kevin P. Hill, Matthew D. Palastro, Brian Johnson, and Joseph W. Ditre Cannabis and Cannabinoid Research, Volume 2.1, 2017 DOI: 10.1089/can.2017.0017 Abstract Introduction : Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence [...]
Lire la suitePsilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers Anna Bravermanová, Michaela Viktorinová, Filip Tylš, Tomáš Novák, Renáta Androvičová, Jakub Korčák, Jiří Horáček, Marie Balíková, Inga Griškova-Bulanova, Dominika Danielová, Přemysl Vlček, Pavel Mohr, Martin Brunovský, Vlastimil Koudelka, Tomáš Páleníček, Psychopharmacology, 2018 https://doi.org/10.1007/s00213-017-4807-2 Received: 12 May 2017 /Accepted: 29 November 2017 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Rationale Disruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of [...]
Lire la suiteIntranasal Ketamine Succeeds for Resistant Depression in Phase 3 Trial Deborah Brauser May 11, 2018 https://www.medscape.com/viewarticle/896510 NEW YORK — Administering intranasal esketamine (Janssen) plus an antidepressant is safe, effective, and well tolerated in adult patients with treatment-resistant depression (TRD), a new phase 3 trial suggests. Dr Vanina Popova In the global study, those who received a newly initiated oral antidepressant combined with esketamine nasal spray (56 or 84 mg) showed a 4-point greater improvement from baseline to 4 weeks on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score than those who received an antidepressant plus placebo, meeting the study's primary endpoint. In addition, the response rate was nearly 70% [...]
Lire la suiteCANNABIS ET CANNABIDIOL : Éléments de Compréhension Dr Sarah Lejczak La Lettre du RESPADD, 35, avril 2019 Depuis 5000 ans, le cannabis ruderalids, sativa ou indica est utilisé dans la pharmacopée humaine de manière informelle pour ses différentes propriétés antihémétiques, antiépileptiques, antispastiques, antalgiques, anxiolytiques, antihypertensives, etc. (1). Suite à son introduction dans l’arsenal pharmaceutique moderne au XIXème siècle et les dérives d’utilisation récréative au cours du XXème siècle, son utilisation a été interdite et reste très controversée de nos jours. Des extraits cannabinoïdes (2) (Delta-9-tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD) et cannabinol (CBN) majoritairement) de la plante ou fabriqués synthétiquement sont utilisés depuis 1985 en tant que médicaments. [...]
Lire la suite3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297 Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]
Lire la suiteChapter : The endocannabinoid system in Fragile X Syndrome Henry G. S. Martin, Daniela Neuhofer and Olivier J.J. Manzoni Fragile X Syndrome : From Genetics to Targeted Treatment, 2017, Pages 241-259 DOI: 10.1016/B978-0-12-804461-2.00012-3 Addresses: INSERM U901, INMED and UMR S901, Aix-Marseille University Marseille 13009, France. Abstract : Endocannabinoid signaling is a finely tuned system of molecules and lipid messengers that modulate neurotransmission in a rapid and sustained manner at many central synapses. The endocannabinoid system is important for many brain activities, but is also implicated in several neuropsychiatric disorders. In this chapter we discuss emerging evidence of dysfunction in endocannabinoid signaling in Fragile X Syndrome from the Fmr1 knockout mouse model. [...]
Lire la suite